Tenax Therapeutics CEO Christopher Giordano and CFO Thomas R. Staab II purchased company stock in open-market transactions.
Giordano acquired 10,850 shares on September 11 and September 15 for approximately $20,087.
Staab purchased 5,675 shares on September 11 for about $10,981.
The company’s share price currently trades near its 52-week low following a significant decline over the past year.
The stock value fell after the Phase 3 LEVEL clinical trial failed to meet its primary endpoint in August 2026.
These executive purchases signal confidence in the company’s long-term prospects despite the recent clinical setback.